What is Anticancer Bioscience?
Based out of Ghengdu, China, Anticancer Bioscience is a medtech company focused on synthetic lethal approaches to precision oncology. The company's work in this specialized area of cancer treatment aims to develop targeted therapies that exploit specific vulnerabilities in cancer cells, aligning with the growing trend towards personalized medicine in the pharmaceutical and biotechnology sectors. The enterprise-level funding suggests a company poised for significant scaling and clinical development.
How much funding has Anticancer Bioscience raised?
Anticancer Bioscience has raised a total of $41M across 2 funding rounds:
Other Financing Round
$10M
Angel/Seed
$31M
Other Financing Round (2021): $10M, investors not publicly disclosed
Angel/Seed (2021): $31M, investors not publicly disclosed
What's next for Anticancer Bioscience?
With substantial enterprise-level funding and a recent strategic investment, Anticancer Bioscience is positioned for accelerated growth and the advancement of its synthetic lethal therapies. This capital infusion is expected to fuel further research and development, potentially leading to expanded clinical trials and the progression of its pipeline candidates towards commercialization. The company's focus on precision oncology indicates a strategic direction aligned with future healthcare demands for more effective and less toxic cancer treatments.
See full Anticancer Bioscience company page
